Peptides: hype vs. science
A recent deep‑dive video argues there are no true anabolic peptides and breaks the market into five categories — most remain unproven, require refrigeration/injection, and are often sourced on a risky gray market. The hosts note an important exception: weight‑loss agents like semaglutide, tirzepatide and retatide are well‑researched and genuinely effective when dosed properly (youtube.com).
The U.S. Food and Drug Administration has designated certain research peptides as bulk substances that “present significant safety risks” and therefore are ineligible for compounding under sections 503A/503B, a policy that has reshaped access to compounds like BPC‑157. (fda.gov ) The U.S. International Trade Commission has moved aggressively against counterfeit imports: Investigation No. 337‑TA‑1377 resulted in notices and a general exclusion order aimed at products containing tirzepatide and named multiple online vendors found in default in 2024–2025. (federalregister.gov ) Semaglutide delivered mean weight loss of 14.9% at 68 weeks in the STEP‑1 trial, as reported in the New England Journal of Medicine, while tirzepatide produced up to 22.5% mean weight loss at 72 weeks in SURMOUNT‑1. (nejm.org ) (nejm.org ) Eli Lilly’s investigational triple‑agonist retatrutide produced a mean reduction of up to 24.2% at 48 weeks in a phase‑2 trial that was published and presented at major scientific meetings, and the company has advanced a TRIUMPH phase‑3 program to follow those results. (jamanetwork.com ) (prnewswire.com ) Branded GLP‑1 injectables carry explicit cold‑chain rules: Wegovy/Ozempic labeling requires refrigeration at roughly 2°C–8°C (36°F–46°F) before first use, and reconstituted research peptides commonly lose stability much faster—guidance documents list typical refrigerated post‑reconstitution windows of about 14–30 days. (accessdata.fda.gov ) (orynxpeptides.com ) Regulators and health journalists have documented a parallel surge of online “research‑chemical” supply lines and influencer‑driven demand, prompting FDA warning letters to vendors and public reporting about contamination, mislabeling, and unsafe marketing practices in 2024–2025. (fda.gov ) (statnews.com )
